What the business is, and whether it's a good one at a fair price.
Operates as a pharmaceutical contract development and manufacturing organisation (CDMO), supplying drug substances and drug products to other pharma and biotech companies, primarily through its Switzerland-based CARBOGEN AMCIS subsidiary. Revenue is split between a CRAMS/CDMO stream that makes APIs and intermediates on a contract basis, including high-margin antibody-drug conjugate (ADC) linker-payload work, and a marketable molecules stream that sells proprietary products such as Vitamin D analogs. The CDMO side ran more than 10 late-phase drug substance projects and more than 30 commercial products in FY26, with ADC linker-payloads contributing about 25% of CDMO revenue. Q4 FY26 revenue of INR 851 crore split between INR 690.8 crore from CDMO (up 21% YoY) and INR 160.5 crore from marketable molecules (up 9.3% YoY); Vitamin D analog margins in the quarter expanded 940 basis points to 21.1% on supplier diversification. A technology transfer of a large molecule from Switzerland to India has been approved, worth about CHF 20-25 million in annual revenue, with India revenue targeted at INR 500 crore+ by FY28. A French drug-product subsidiary lost EUR 9 million in FY26, with EBITDA breakeven targeted for FY28. The cost base is dominated by employees at 49.4% of FY26 revenue, followed by other opex at 17.4% and materials at 16.6%.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from DISHMAN CARBO AMCIS LTD's filed financials and exchange disclosures
DISHMAN CARBO AMCIS LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol DCAL.
Yes. Over the trailing twelve months DISHMAN CARBO AMCIS LTD reported a net profit of ₹16 Cr on revenue of ₹2,901 Cr.
Not in the latest reported year — DISHMAN CARBO AMCIS LTD's dividend payout for FY26 was nil.
No. Debt stands at 0.42× equity, and it carries net debt of ₹1,988 Cr. That is lower than 22% of its 171 Pharmaceuticals peers.
On trailing P/E, DISHMAN CARBO AMCIS LTD ranks 165 of 169 in Pharmaceuticals — cheaper than 2% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session DISHMAN CARBO AMCIS LTD moves 1.74% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by DISHMAN CARBO AMCIS LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
